Ixazomib (Ninlaro), the first oral PI All were approved for use in relapsed/refractory multiple myeloma, although daratumumab was also approved for newly diagnosed disease.

New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...

Introduction Multiple myeloma (MM) is a malignancy derived from terminally differentiated plasma cells and has become the second most prevalent hematological cancer (1). Extramedullary disease (EMD) ...

Kyphoplasty is being used to treat painful osteolytic or fractured vertebrae, but will it become a key treatment option for patients with vertebral osteolyses from multiple myeloma?

The EMA has extended the indications for Darzalex (daratumumab) to the treatment of adults at high risk of developing multiple myeloma.

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

Toronto, Ontario-- (Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for ...

Fatigue, bone pain, and frequent infections can all be signs of the blood cancer multiple myeloma, which often has no early distinctive symptoms.

NICE leads the way in approving breakthrough treatment for multiple myeloma People in England will become the first in the world to receive belantamab mafodotin for this indication following our ...

Could you briefly summarize the initial CARTITUDE-1 results and explain their significance for patients with relapsed/refractory multiple myeloma? CARTITUDE-1 was a phase 1b/2 trial, which was ...

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.